14-day Premium Trial Subscription Sign Up For FreeGet Free

ADMA Biologics Inc Stock Forecast NASDAQ:ADMA

Price Target and Analyst Ratings

Most Recent Rating

On September 20, 2021 "Jefferies Financial Group" gave "$10.00" rating for ADMA. The price target was changed from $1.27 to 1.9%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-09-20 $10.00 Initiated by Jefferies Financial Group $1.25 $1.27→1.9%
2021-08-12 $7.00 - $6.00 Target Lowered by HC Wainwright $1.51 $1.53
2021-07-26 $7.00 Reiterated by HC Wainwright $1.63 $1.61+1.9%
2021-07-06 Buy Target Lowered by HC Wainwright $1.51 $10.00 → $7.00
2021-04-05 Buy Reiterated by Jefferies Financial Group $1.83 $10.00
2021-04-01 Outperform Target Lowered by Raymond James $1.83 $7.00 → $6.00
2021-03-26 Buy Reiterated by Maxim Group $1.81 $6.00
2021-03-26 Outperform Target Lowered by Raymond James $1.81 $7.00 → $6.00
2021-01-04 Buy Target Lowered by HC Wainwright $2.11 $12.00 → $11.00
2021-01-04 Buy Reiterated by HC Wainwright $2.11
2020-10-01 Outperform Target Raised by Raymond James $2.23 $7.00 → $9.00
2020-08-06 Buy Initiated by Oppenheimer $2.86 $6.00
2020-08-06 Buy Reiterated by HC Wainwright $2.86 $12.00
2020-07-28 Buy Reiterated by HC Wainwright $2.79 $12.00
2020-05-22 Buy Initiated by Maxim Group $2.84 $6.00
2020-05-22 Buy Reiterated by HC Wainwright $2.84 $12.00
2020-05-07 Outperform Target Lowered by Oppenheimer $2.62 $14.00 → $7.00

ADMA Stock Trend

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -24.41% during the next 3 months and, with a 90% probability hold a price between $0.84 and $1.04 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-23 $1.11 $1.24 $1.37
2021-09-24 $1.10 $1.23 $1.36
2021-09-27 $1.10 $1.22 $1.35
2021-09-28 $1.09 $1.22 $1.35
2021-09-29 $1.08 $1.21 $1.34
2021-09-30 $1.07 $1.20 $1.33
2021-10-01 $1.07 $1.20 $1.33
2021-10-04 $1.06 $1.19 $1.32
2021-10-05 $1.05 $1.18 $1.31
2021-10-06 $1.05 $1.18 $1.30
2021-10-07 $1.04 $1.17 $1.30
2021-10-08 $1.03 $1.16 $1.29
2021-10-11 $1.02 $1.15 $1.28
2021-10-12 $1.02 $1.15 $1.28
2021-10-13 $1.01 $1.14 $1.27
2021-10-14 $1.00 $1.13 $1.26
2021-10-15 $1.00 $1.13 $1.26
2021-10-18 $0.99 $1.12 $1.25
2021-10-19 $0.98 $1.11 $1.24
2021-10-20 $0.98 $1.10 $1.23
2021-10-21 $0.97 $1.10 $1.23
2021-10-22 $0.96 $1.09 $1.22
2021-10-25 $0.95 $1.08 $1.21
2021-10-26 $0.95 $1.08 $1.21
2021-10-27 $0.94 $1.07 $1.20
2021-10-28 $0.93 $1.06 $1.19
2021-10-29 $0.93 $1.06 $1.18
2021-11-01 $0.92 $1.05 $1.18
2021-11-02 $0.91 $1.04 $1.17
2021-11-03 $0.91 $1.03 $1.16

About ADMA Biologics Inc

ADMA Biologics ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate is RI-002, a plasma-derived, polyclonal immune globulin intravenous that is in Phase III clinical study for the treatment of primary immune deficiency disease. The company also operatesADMA BioCenters Georgia, Inc, which is a... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT